{
    "root": "d328a518-17cf-49d2-af3c-bbe4b5057613",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril Maleate",
    "value": "20250507",
    "ingredients": [
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Sodium Bicarbonate",
            "code": "8MDF5V39QO"
        },
        {
            "name": "CI 77491",
            "code": "1K09F3G675"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "product : 50090-3275 ndc : 50090-3275-0 30 tablet bottle ndc : 50090-3275-1 100 tablet bottle , plastic ndc : 50090-3275-4 90 tablet bottle , plastic",
    "adverseReactions": "enalapril maleate contraindicated patients hypersensitive product patients history angioedema related previous treatment angiotensin-converting enzyme inhibitor patients hereditary idiopathic angioedema . coadminister aliskiren enalapril maleate patients diabetes ( , ) . enalapril maleate contraindicated combination neprilysin inhibitor ( e.g . , sacubitril ) . administer enalapril maleate within 36 hours switching sacubitril/valsartan , neprilysin inhibitor ( , head neck angioedema ) .",
    "warningsAndPrecautions_original": "Product:    50090-3275\n                  NDC:    50090-3275-0   30 TABLET in a BOTTLE\n                  NDC:    50090-3275-1   100 TABLET in a BOTTLE, PLASTIC \n                  NDC:    50090-3275-4   90 TABLET in a BOTTLE, PLASTIC",
    "adverseReactions_original": "Enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see \n                        PRECAUTIONS, Drug Interactions\n                     ).\n                  Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see \n                        WARNINGS, Head and Neck Angioedema\n                     )."
}